|
Atticus Pharma Inc., an SC Launch Inc. Portfolio Company focused on immunodermatology and associated conditions, announced completion of subject enrollment in the human clinical study of ATC-002 in females diagnosed with androgenic alopecia. As planned, a total of 96 subjects were enrolled and randomly assigned to receive: (i) a low dose of ATC-002, (ii) a high dose of ATC-002, or (iii) placebo. Read more.
|